In vivo neutralization of Vascular Endothelial Growth Factor (VEGF)/Vascular Permeability Factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth

International Journal of Oncology

Volumn 8, Issue 3, 1996, Pages 505-511

  Olson, Timothy A ^a   Mohanraj, D ^a   Ramakrishnan, S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Angiogenesis; Ascites; Ovarian cancer; Tumor neovascularization; Vascular endothelial growth factor (VEGF); Vascular permeability factor (VPF)

Indexed keywords

VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES TUMOR; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SURVIVAL; TUMOR XENOGRAFT;

EID: 0029934658     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.8.3.505     Document Type: Article

References (32)

1. Wingo PA, Tong T, Bolden S: Cancer statistics 1995. CA Cancer J Clin 45: 8-30, 1995.
2. Roszkowski P, Wronkowski Z, Szamborski J and Romejko M: Evaluation of selected prognostic factors in ovarian cancer. Eur J Gynaecol Oncol 14: 140-145, 1993.
3. Nagy JA, Herzberg KT, Dvorak JM and Dvorak HF: Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 53: 2631-2643, 1993.
4. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, Sioussat TM, Dvorak HF: Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability and ascites fluid accumulation. Cancer Res 55: 360-368, 1995.
5. Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
6. Neufeld G, Tessler S, Goren HG, Cohen T and Levi BZ: Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 5: 89-97, 1994.
7. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM and Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303-324 ,1993.
8. Dvorak HF, Nagy JA, Dvorak JT and Dvorak AM: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133: 95-109, 1988.
9. Nagy JA, Meyers MS, Masse EM, Herzberg KT, Dvorak HF: Pathogenesis of ascites tumor growth: Influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 55: 369-375, 1995.
10. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF: Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 55: 376-385, 1995.
11. Yeo K-T, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF, and Yeo T-K: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 53: 2912-2918, 1993.
12. McClure N, Healy DL, Rogers PAW, Sullivan J, Beaton L, Haning Jr RV, Connolly DT and Robertson DM: Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344: 235-236, 1994.
13. Plate KH, Breier G, Millauer B, Ullrich A and Risau W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53: 5822-5827, 1993.
14. Brown LF, Berse B, Jackman RW, Tongnazzi K, Manseau EJ, Senger DR and Dvorak HF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727-4735, 1993.
15. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T and Terada M: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54: 4233-4237, 1994.
16. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips H and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
17. Warren RS, Yuan H, Matli MR, Gillett NA and Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789-1797, 1995.
18. Millauer B, Shawver LK, Plate KH, Risau W and Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature 367: 576-579, 1994.
19. Olson TA, Mohanraj D, Carson LF and Ramakrishnan S: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54: 276-280, 1994.
20. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR and Smith SK: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506-516, 1995.
21. Mohanraj D, Olson T and Ramakrishnan S: Expression of biologically active human vascular permeability factor in yeast. Growth Factors 12: 17-27, 1995.
22. Fryxell D, Li BY, Mohanraj D, Johnson B and Ramakrishnan S: Genetic construction of a phosphorylation site in ricin A chain: specific radiolabeling of recombinant proteins for localization and degradation studies. Biochem Biophys Res Commun 210: 253-259, 1995.
23. 3 for angiogenesis. Science 264: 569-571, 1994.
24. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
25. Ozols RF, Rubin SC, Dembo AJ and Robboy S: Epithelial ovarian cancer. In: Principles and Practice of Gynecologic Oncology. WJ Hoskins, CA Perez and RC Young (eds.) pp731-781, Lippincott, Philadelphia, 1992.
26. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
27. Berchuck A, Kamel A, Whitacker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge D, Clarke-Pearson DL, Marks SA, McKenzie S, Yin S and Bast RC: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-409, 1990.
28. Ferrara N, Winer J, Burton T, Rowland A, Siegel M, Phillips H, Terrell T, Keller G and Levinson A: Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest 91: 160-170, 1993.
29. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1991.
30. Bookman MA: Biologic therapies for gynecologic cancer. Curr Opin Oncol 7: 478-484, 1995.
31. Jain RK: Therapeutic implications of tumor physiology. Curr Opin Oncol 3: 1105-1108, 1991.
32. Saltzman AK, Olson TA, Mohanraj D, Carson LF and Ramakrishnan S: Prevention of postoperative adhesion by an antibody to vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) in a murine model. Am J Obstet Gynecol (In press).